<DOC>
	<DOCNO>NCT00163033</DOCNO>
	<brief_summary>Estetrol natural compound produce fetus fetal life circulates unborn child mother . It estrogenic compound . In study safety tolerability 28 day oral administration estetrol healthy postmenopausal woman investigate . In addition , pharmacokinetics pharmacodynamic parameter study . The low dose 2 mg estetrol directly compare 2 mg estradiol .</brief_summary>
	<brief_title>Study Evaluate 3 Dosages Estetrol After 28 Days Administration Healthy Postmenopausal Women</brief_title>
	<detailed_description>This partly randomize open-label study healthy postmenopausal woman . Groups treat follow sequence : first 2 mg estetrol group together 2 mg estradiol group . When dose 2 mg estetrol safe tolerability good , next high dose group estetrol start , possibly follow two next high dose group previous dose group safe tolerability good . The primary objective study investigate safety tolerability estetrol multiple dose 28 day . Furthermore steady state pharmacokinetics pharmacodynamic parameter estetrol investigate . In addition , pharmacokinetics pharmacodynamic effect 2 mg estetrol group compare 2 mg estradiol group . In group 5 postmenopausal woman include &gt; 50 hot flush per week 5 postmenopausal woman &lt; 10 hot flush per week . These criterion set get homologous composition group .</detailed_description>
	<criteria>Postmenopausal woman older 70 year age time screen ( menopause define ≥ 6 month amenorrhea serum folliclestimulating hormone [ FSH ] level ≥ 40 IU/L serum E2 &lt; 73 pmol/L ) . Body mass index 1830 kg/m2 inclusive . Good physical mental health , judge Investigator , determine medical history , physical examination , clinical laboratory value , vital sign , electrocardiogram ( ECG ) recording . Willing give write informed consent . Either &gt; 50 hot flush per week &lt; 10 hot flush per week Clinically significant abnormal result routine hematology , serum biochemistry , urinalysis , and/or ECG opinion Investigator screening . Clinically significant abnormal mammogram ( presence noncystic mass ) within one year study start . Clinically significant abnormality uterus and/or ovary detect examination and/or ultrasound ( nonphysiological ovarian mass significant uterine pathology endometrium great 6 mm ) . A cervical smear clinically relevant abnormal cytology within one year study start . Previous use estrogen/progestogen within : 6 month depot preparation . 8 week oral preparation progestogen contain intrauterine device ( IUD ) . 4 week transdermal preparation . Use hormone contain implant time . Contraindications use steroid : A history , exist thromboembolic , cardiovascular , cerebrovascular disorder . A history , exist condition predispose , prodrome , thrombosis . A known defect blood coagulation system ( e.g . deficiency antithrombinIII [ ATIII ] , protein C , S , activate protein C [ APC ] resistance ) . A medical history positive presence one risk factor vascular disease ( e.g . dyslipoproteinemia ; diabetes mellitus ; hyperhomocysteinemia ; systemic lupus erythematosus ; chronic inflammatory bowel disease ; smoking ; venous thromboembolism sibling parent age 50 , arterial disease sibling parent age 3035 ) . Hypertension , i.e . systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg . Disturbance liver function : cholestatic jaundice , history jaundice pregnancy jaundice due previous estrogen use , Rotor syndrome DubinJohnson syndrome . Known suspected estrogendependent tumor endometrial hyperplasia Undiagnosed vaginal bleeding . Porphyria . A history pregnancy previous estrogen use severe pruritus , herpes gestationis , deterioration otosclerosis . Any medication ( include overthecounter [ OTC ] product ) 14 day prior day dose except occasional nonsteroidal antiinflammatory drug ( NSAID ; e.g . ibuprofen ) ; paracetamol permit . Any enzyme affecting drug 30 day prior Day 1 use griseofulvin , primidone , oxcarbazepine , topiramate , felbamate , herbal remedy contain hypericum perforatum ( St. John 's wort ) . Presence significant allergy serious disease . Smoking 10 cigarette equivalent per day . Administration investigational drug within 3 month start study medication . A history ( within 12 month ) alcohol drug abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>phase I study</keyword>
</DOC>